Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses

Bibliography

• LOCKE GR, TALLEY NJ, FETT SL et al: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 112 (5) :1448–1456.
   PubMed Web of Science ®Google Scholar
• DEVAULT KR, CASTELL DO: Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am. Gastroenterol. (1999) 94 (6) :1434–1442.
   PubMed Web of Science ®Google Scholar
• O'CONNOR JB, PROVENZALE D, BRAZER S: Economic considerations in treatment of gastroesophageal reflux: a review. Am. j Gastroenterol (2000) 95(12):3356–3364.
   PubMedGoogle Scholar
• BARRADELL LB, FAULDS D, D: Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs (1992) 44:225–250.
   Google Scholar
• BRUNTON LL: Agents for control of gastric acidity and treatment of peptic ulcers. In: Goodman's and Gillman's The Pharmacologic Basis of Therapeutics. JG, Limbird LE, Molinod PB, Ruddon RW (Eds.), McGraw-Hill, New York (1996):901–915.
   Google Scholar
• BESANCOM M, SIMON A, SACHS G: The critical cysteine in the gastric H, K ATPase for inhibition of acid secretion by proton pump inhibitors. Gastroenterology (1995) 108:A59.
   Google Scholar
• TAP PHARMACEUTICALS, INC: Prevacid® (lansoprazole) delayed-release capsules. In: Physicians' Desk Reference. Medical Economics Co., Inc. Montvale, NJ, USA (2001):3189–3194.
   Google Scholar
• BRULEY DES VARANNES S, LEVY P, LARTIGUE S et al: Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment. Pharmacol. Ther. (1994) 8:309–314.
   PubMedGoogle Scholar
• DAMMANN HG, VON ZUR MUHLEN A, BALKS HJ et al: The effects of lansoprazole, 30 or 60 mg daily on intragastric pH and on endocrine function in healthy volunteers. Aliment. Pharmacol Ther. (1993) 7(2):191–196.
   PubMedGoogle Scholar
• KATZ PO, HATLEBAKK JG, CASTELL DO: Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment. Pharmacol. Ther. (2000) 14(6):709–714.
   PubMedGoogle Scholar
• GREMSE DA, TOLIA V, PAN WJ et al.: Pharmacokinetics/Pharmacodynamics of lansoprazole in pediatric patients with symptomatic gastroesophageal reflux disease. j Pediatr. Gastroenterol. Nutr (2000) 31(9):A144.
   Google Scholar
• GUNASEKARAN T, PAN WJ, TORRES-PINEDO R et al: Pharmacokinetics of lansoprazole in adolescent patients with gastroesophageal reflux disease. Gastroenterology (2000) 118:A1241.
   Google Scholar
• OGOSHI K, KATO T, SAITO S, NIWA, WATANABE H et al: Clinical study of AG-1749 (1 ansoprazole) : effects on serum gastrin levels and gastric mucosal ECL density, etc. Yakuri to Chiryo (1991) 19(3):933–946.
   Google Scholar
• EL NUJUMI A, WILLIAMS C, ARDILL JE, OIEN K, MCCOLL KE: Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment. Gut (1998) 42(2):159–165.
   PubMedGoogle Scholar
• ABE T, SATO S, SUZUKI T, MIYAJIMA H: Thirteen week oral toxicity study of lansoprazole (AG-1749) in rats. Yakuri to Chiryo (1990) 18\(Suppl. 10):S2663–S2678.
   Google Scholar
• MCTAVISH D, BUCKLEY MM-T, HEEL RC: Omeprazole: an updated review of its pharmacology and therapeutic use in acid-related disorders. Dugs (1991) 42(1):138–170.
   Google Scholar
• EISSELE R, BRUNNER G, SIMON B, SOLCIA E, ARNOLD R: Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology (1997) 112(3):707–717.
   PubMedGoogle Scholar
• ZIMMERMANN AE, KATONA BG:: a comprehensive review. Pharmacotherapy (1997) 17(2):308–326.
   PubMedGoogle Scholar
• HOWDEN CE, KENYON CJ, BEASTAL GH, REID JL: Inhibition by lansoprazole of adrenocortical response to ACTH: clinical studies and experiments on bovine adrenal cortex in vitro. Chit. Sci. (1986) 70:99–101.
   Google Scholar
• DEHLHOTAL-LANDES B, COURNOT A, VERMERIE N et al.: The effect of food and antacids on lansoprazole absorption and disposition. Eur. j Dug Metab. Pharmacokinet. (1991) (Special Issue No. III):315–320.
   Google Scholar
• RICHTER JE, KOVACS TO, GRESKI-ROSE PA, HUANG B, FISHER R: Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment. Pharmacol. Ther. (1999) 13(6):795–804.
   PubMedGoogle Scholar
• BARDHAN KD, HAWKEY CJ, LONG RG et al: Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK lansoprazole clinical research group. Aliment. Pharmacol. Ther. (1995) 9(2):145–151.
   PubMedGoogle Scholar
• SONTAG SJ, KOGUT DG, R et al: Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. Am. J Gastroenterol. (1997) 92(3):429–437.
   PubMedGoogle Scholar
• FELMAN M, HARFORD WV, FISHER RS et al.: Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K+ -ATPase inhibitor: a controlled, double-blind study. Am. J Gastroenterol. (1993) 88(8):1212–1217.
   PubMedGoogle Scholar
• BARDHAM KD: Is there any acid pepticdisease that is refractory to proton pump inhibitors? Aliment. Pharmacol. Ther. (1993) 7\(Suppl. 1):13–24.
   Google Scholar
• ROBINSON M, CAMPBELL DR, SONTAG S, SABESIN SM: Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy: lansoprazole a new proton pump inhibitor. Dig. Dis. Sci. (1995) 40(3):590–597.
   PubMedGoogle Scholar
• SHARMA VK, LEONTIADIS GI, HOWDEN CW: Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment. Pharmacol. Ther. (2001) 15(2):227–231.
   PubMedGoogle Scholar
• MEE AS, ROWLEY JL AND THE LANSOPRAZOLE CLINICAL RESEARCH GROUP: Rapid symptom in reflux oesophagitis: a comparison of and omeprazole. Aliment. Pharmacol. Ther. (1996) 10(2):757–763.
   PubMedGoogle Scholar
• RICHTER J, KAHRILAS P, SONTAG S et al.: Speed of heartburn relief: lansoprazole versus omeprazole. Am. j Gastroenterol. (2000) 95(9):2431A.
   Google Scholar
• KRUEGER KJ, DIPALMA JA: Changing clinical perspectives toward gastroesophageal reflux. South Med. (1996) 89(5):548–550.
   Google Scholar
• ROBINSON M, LANZA F, AVNER D, HABER M: Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. Ann. Intern. Med. (1996) 124(10):859–867.
   PubMed Web of Science ®Google Scholar
• FRANCO MT, SALVIA G, TERRIN G et al.: Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig. Liver Dis. (2000) 32(8):660–666.
   PubMedGoogle Scholar
• TOLIA V, FERRY G, GUNASEKARAN T, HUANG B, KEITH R, BOOK L: Efficacy of lansoprazole in the treatment of GERD in children. Am. j Gastroenterol. (2000) 95(9):2446A.
   Google Scholar
• TAKEMOTO T, NAMIKI M, GOTO Y, MATSUO Y, MIWA T: A study of clinical usefulness of lansoprazole (AG-1749) in treating gastric ulcer: a comparison with famotidine by multiclinic, double-blind technique. Rinshoseliiribyo (1991) 21(2):327–345.
   Google Scholar
• BARDHAN KD, AHLBERG J, HISLOP WS et al.: Rapid healing of gastric ulcers with lansoprazole. Aliment. Pharmacol. Ther. (1994) 8(2):215–220.
   PubMedGoogle Scholar
• FLORENT C, AUDIGIER JC, BOYER J eta].: Efficacy and safety of lansoprazole in the treatment of gastric ulcer: a multicentre study. Eur. I Gastroenterol. Hepatol. (1994) 6:1135–1139.
   Google Scholar
• HORN J: The proton pump inhibitors: similarities and differences. Chit. Ther. (2000) 22(3):266–280.
   Google Scholar
• HAWKEY CJ, LONG RG, BARDHAN KD et al: Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut (1993) 34(10):1458–1462.
   PubMedGoogle Scholar
• DOBRILLA G, PIAZZI L, FIOCCA R: Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial. Chit. Ther. (1999) 21:1321–1332.
   Google Scholar
• EKSTROM P, CARLING L, UNGE P et Lansoprazole versus omeprazole in active ulcer. Land. j Castroenterol (1995) 30:210–215.
   Google Scholar
• PETITE J-P, SLAMA J-L, LICHT H et al: Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. Castroenterol Glitz Biol. (1993) 17:334–340.
   PubMedGoogle Scholar
• LOUW JA, VAN RENSBURG C, SIMJEE AE et al: Lansoprazole versus omeprazole in duodenal ulcer healing. Safr. Med. J. (1993) 83:777.
   Google Scholar
• KOVACS TO, CAMPBELL D, RICHTER J, HABER M, JENNINGS DE, ROSE P: Double blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists. Aliment. Pharmacol. Ther. (1999) 13(1):959–967.
   PubMedGoogle Scholar
• BRUNNER G, ARNOLD R, HENNIG U, FUCHS W: An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment. Pharmacol. Ther. (1993) 7\(Suppl. 1):51–55.
   Google Scholar
• BRUNNER G, CREUTZFELDT W, HARKE U et al: Therapy with omeprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Digestion (1988) 38:80–90.
   Google Scholar
• AGRAWAL NM, CAMPBELL DR, SAFDI MA et al: Superiority of lansoprazole vs. ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. Arch. Int. Med. (2000) 160(10):1455–1461.
   Google Scholar
• NIH CONSENSUS DEVELOPMENT PANEL ON HELICOBACTER PYLORI IN PEPTIC ULCER DISEASE: Helicobacter pylori in peptic ulcer disease. JAMA (1994) 272:65–69.
   PubMed Web of Science ®Google Scholar
• THE EUROPEAN HELICOBACTER PYLORISTUDY GROUP: European concepts in the management of Helicobacter pylori infection: the Maastricht consensus report. Cut (1997) 41:8–13.
   Google Scholar
• LABENZ J, BORSCH G: Toward an treatment of Helicobacter pylori-positive peptic ulcers. Am. J. Castroenterol (1995) 90:692–694.
   PubMedGoogle Scholar
• TSUCHIYA M, IMAMURA L, PARK J-B,KOBASHI K: Helicobacter pylori orease inhibition by rabeprazole, a proton-pump inhibitor. Biol. Pharm. Bull. (1995) 18:1053–1056.
   PubMed Web of Science ®Google Scholar
• MAUCH F, BODE G, P: Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton-pump inhibitors (Letter). Am. Castroenterol (1993) 88:1801–1802.
   PubMed Web of Science ®Google Scholar
• NAKAO M, MALFERTHEINER P: Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori Helicobacter (1998) 3:21–27.
   Google Scholar
• SCHWARTZ H, KRAUSE R, SAHBA B et al.: Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Am. J. Castroenterol (1998) 93(4):584–590.
   PubMed Web of Science ®Google Scholar
• LAZZARONI M, BARGIGGIA S, PORRO GB: Triple therapy for with ranitidine or lansoprazole in the treatment of Helicobacter pylori associated duodenal ulcer. Am. J. Castroenterol (1997) 92 (4):649–652.
   PubMedGoogle Scholar
• COLIN-JONES DG: Safety of lansoprazole. Aliment. Pharmacol Ther. (1993) 7\(Suppl. 1):56–60.
   Google Scholar
• QURESHI W, RASHID S: Zollinger-Ellison syndrome: improved treatment options for this complex disorder. Postgrad. Med. (1998) 104:155–58;163-164.
   Google Scholar
• STEDMAN CAM, BARCLAY ML: Review article: comparison of the, acid suppression, and efficacy of proton pump inhibitors. Aliment. Pharmacol Ther. (2000) 14:963–978.
   PubMedGoogle Scholar
• HIRSCHOWITZ BI, MOHNEN J, SHAW S: Long-term treatment with for patients with Zollinger-Ellison syndrome. Aliment. Pharmacy] Ther. (1996) 10:507–522.
   PubMedGoogle Scholar
• SPENCER CM, FAULDS D: Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs (1994) 48:404–430.
   Google Scholar
• LANGTRY HD, WILDE MI: Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs (1997) 54:473–500.
   Google Scholar
• TOLMAN KG, SANDERS SW, BUCHI KN et al.: The effects of oral doses of lansoprazole and omeprazole on gastric pH. J. Chit. Castroenterol (1997) 24:65–70.
   Google Scholar
• YEOMANS ND, DENT J: Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion? Aliment. Pharmacol. Ther. (2000) 14:267–271.
   Google Scholar
• WALDUM HL, BRENNA E: Personal review: is profound acid inhibition safe? Pharmacol Ther. (2000) 14:15–22.
   Google Scholar
• FRESTON JW: Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Am. J. Castroenterol (1997) 92(4):515–555.
   Google Scholar
• ROUX A, NALINE R, MOLINIER P et al.: Effect of lansoprazole and omeprazole on the metabolism of theophylline and antipyrine in man. &L I. Drug Metab. Pharmacolcinet. (1993) 18:125A.
   Google Scholar
• FRESTON J, CHIU YL, PAN WJ et al: Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. Am. J. Castroenterol (2001) 96(7):2058–2065.
   PubMedGoogle Scholar